Microbot signs clinical trial agreement for LIBERTY robotic system

From Nasdaq, Inc.: 2024-07-04 13:49:00

Microbot Medical Inc. (MBOT) signed a clinical trial agreement with Baptist Hospital of Miami for its LIBERTY Endovascular Robotic Surgical System, approved for trial at the Miami Cardiac & Vascular Institute and Miami Cancer Institute.

LIBERTY is a single-use endovascular robotic system designed to streamline procedures, eliminating large capital equipment needs, reducing radiation exposure, and physician strain.

Market prospects project the robotic-assisted endovascular systems market size to exceed $214.7 million by 2033, driven by rising cardiovascular illnesses and demand for minimally invasive surgical procedures.

Microbot’s IDE approval for LIBERTY comes after FDA approval for a pivotal human clinical trial and collaboration with Corewell Health to showcase system capabilities.

Stock performance for MBOT has seen a 36% loss year to date, amid industry growth of 3.4%, leading to a Zacks Rank #4 (Sell) for the company.

Other notable medical stocks with strong rankings include Hims & Hers Health, Inc. (HIMS), The Joint Corp. (JYNT), and Medpace Holdings (MEDP), each showing positive performance and growth in their respective sectors.



Read more at Nasdaq, Inc.: Microbot (MBOT) Inks a New Agreement to Begin Trial on LIBERTY